Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00671736
Recruitment Status : Completed
First Posted : May 5, 2008
Last Update Posted : August 27, 2009
Information provided by:
AOP Orphan Pharmaceuticals AG

Brief Summary:
This is a dose-finding study for the investigational product Lancovutide (Moli1901) in the exploratory phase IIb to establish minimum effective dose, optimal dose, and maximum safe dose. Additionally, the tolerability of Moli1901 shall be investigated.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: Moli1901 Drug: Moli1901 placebo Phase 2

Detailed Description:
Study Moli1901-010B is a multi center, parallel group, placebo controlled, double-blind efficacy and safety evaluation of three different dosage schedules of aerosolized Moli1901 in adolescents (12 years of age or older), and adults. Study will start with a screening period (visit 1) followed by an 8 weeks double blind comparative treatment period (visit 2-7). Thereafter, subjects will be observed for additional 4 weeks without treatment (follow-up period and visit 8). Spirometry, pulse oximetry and other safety measurements will be performed up to 120 min after study medication inhalation. The study will be conducted in 30 sites in 9 European countries.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults With Cystic Fibrosis
Study Start Date : October 2007
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Experimental: 1
daily inhalation
Drug: Moli1901
2,5 ml inhalation solution, 8 weeks treatment period
Other Name: Lancovutide, 2622U90, duramycin

Experimental: 2
inhalation every other day
Drug: Moli1901
2,5 ml inhalation solution, 8 weeks treatment period
Other Name: Lancovutide, 2622U90, duramycin

Experimental: 3
inhalation twice a week
Drug: Moli1901
2,5 ml inhalation solution, 8 weeks treatment period
Other Name: Lancovutide, 2622U90, duramycin

Placebo Comparator: 4
daily inhalation
Drug: Moli1901 placebo
2,5 ml placebo solution, 8 weeks treatment period

Primary Outcome Measures :
  1. The change in the percentage of the predicted FEV1 (forced expiratory volume in first second) value [ Time Frame: at every study visit ]

Secondary Outcome Measures :
  1. The ensemble of two subject reported clinical scores, which are physical dimensions of the self-report, disease-specific quality of life test, the cystic fibrosis questionnaire in the revised version [ Time Frame: every 2 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body mass index
  • Confirmed diagnosis of cystic fibrosis
  • FEV1 between 50% and 85% of predicted
  • Oxygen saturation level measured by pulse oximetry (SpO2) >90 % on room air

Exclusion Criteria:

  • Bronchial hyperresponsiveness
  • Unstable lung function
  • Pulmonary disease such as pneumonia, tuberculosis, or lung cancer
  • Acute upper respiratory tract infection within the last 2 weeks
  • Acute lower respiratory tract infection (requiring antibiotics or hospitalization) within the last 4 weeks
  • Pulmonary exacerbation within the last 4 weeks
  • Changes from routine maintenance therapy within the last 4 weeks
  • Scheduled changes to inhaled antibiotics regimen during the course of the study
  • Receive or are planned to receive any treatment via "on-off" regimen (e.g. Tobramycin - TOBI®); last dose of any "on-off" treatment within the last 6 weeks
  • Any clinically significant liver, renal, cardiac, neurological, or hematological disease
  • ABPA or colonization with Burkholderia cepacia
  • Poorly controlled diabetes mellitus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00671736

Medical University
Graz, Austria, 8086
Sponsors and Collaborators
AOP Orphan Pharmaceuticals AG
Principal Investigator: Ernst Eber, Prof Dr Medical University of Graz

Additional Information:
Responsible Party: Nina Vartyan-Böhm, PhD, AOP Orphan Pharmaceuticals AG Identifier: NCT00671736     History of Changes
Other Study ID Numbers: Moli1901-010B
EudraCT No 2006-006693-24
First Posted: May 5, 2008    Key Record Dates
Last Update Posted: August 27, 2009
Last Verified: August 2009

Keywords provided by AOP Orphan Pharmaceuticals AG:
cystic fibrosis

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases